Breast Cancer Research · 2013 · 72 citations · 43 references
Life SciencesOncologyPharmacologyApoptosisCell SignalingSignal TransductionApoptosis In CancerApoptosis RegulationApoptosis ResistanceApoptotic SignalingCancer Cell SignalingSignal Transduction In CancerApoptosis Regulation By PhosphatasesCell Viability AssaysPhosphatase Enzyme ActivityPhosphatase InhibitionProtein Tyrosine Phosphatase InhibitorsSorafenib TherapyStat3 SignalingWestern Blot Analysis
INTRODUCTION: Signal transducers and activators of transcription 3 (STAT3) signaling is constitutively activated in various cancers including breast cancer and has emerged as a novel potential anti-cancer target. STAT3 has been demonstrated to be a target of sorafenib, and a protein tyrosine phosphatase Src homology 2-domain containing tyrosine phosphatase 1 (SHP-1) has been demonstrated to downregulate p-STAT3 via its phosphatase activity. Here, we tested the efficacy of two sorafenib analogues, SC-1 and SC-43, in breast cancer cells and examined the drug mechanism. METHODS: Breast cancer cell lines were used for in vitro studies. Cell viability was examined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis was examined by flow cytometry and western blot. Signal transduction pathways in cells were assessed by western blot. In vivo efficacy of sorafenib, SC-1 and SC-43 was tested in xenografted nude mice. RESULTS: SC-1 and SC-43 induced more potent apoptosis than sorafenib, in association with downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines (HCC-1937, MDA-MB-468, MDA-MB-231, MDA-MB-453, SK-BR3, MCF-7). Overexpression of STAT3 in MDA-MB-468 cells protected the cells from apoptosis induced by sorafenib, SC-1 and SC-43. Moreover, SC-1 and SC-43 upregulated SHP-1 activity to a greater extent than sorafenib as measured by in vitro phosphatase assays. Knockdown of SHP-1 by siRNA reduced apoptosis induced by SC-1 and SC-43. Importantly, SC-1 and SC-43 showed more efficacious antitumor activity and p-STAT3 downregulation than sorafenib in MDA-MB-468 xenograft tumors. CONCLUSIONS: Novel sorafenib analogues SC-1 and SC-43 induce apoptosis through SHP-1 dependent STAT3 inactivation and demonstrate greater potency than sorafenib in human breast cancer cells.
43
SEER Cancer Statistics Review, 1975-2003
Lynn A. G. Ries, D. Harkins, Martin Krapcho et al. · ScholarWorks - Georgia State University (Georgia State University) · 2006 · 11.5K citations · Full text
Medicine, Biostatistics, Oncology +12
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Paul Wan, Mathew J. Garnett, S. Mark Roe et al. · Cell · 2004 · 2.8K citations · Full text